You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Non-Hodgkin Lymphomas

  • Authors: Christopher Flowers, MD, MS; Michael Buege, PharmD, BCOP; Amy Goodrich, RN, MSN, CRNP-AC; Kami Maddocks, MD; Loretta Nastoupil, MD; Gilles Salles, MD, PhD
  • CME / ABIM MOC / CE Released: 10/13/2022
  • Valid for credit through: 10/13/2023
Start Activity

  • Credits Available

    Physicians - maximum of 1.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.25 ABIM MOC points

    Nurses - 1.25 ANCC Contact Hour(s) (1 contact hours are in the area of pharmacology)

    Pharmacists - 1.25 Knowledge-based ACPE (0.125 CEUs)

    IPCE - 1.25 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematologists/oncologists, nurses, nurse practitioners (NPs), physician assistants (PAs), and pharmacists involved in the care of patients with non-Hodgkin lymphomas.

The goal of this activity is that learners will be better able to personalize treatment for patients with non-Hodgkin lymphomas by integrating clinical trial data and evidence-based recommendations on novel therapies.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Recent clinical trial data on treatment strategies for non-Hodgkin lymphoma
  • Have greater competence related to
    • Selecting evidence-based treatment for patients with non-Hodgkin lymphoma
    • Managing adverse events associated with current therapies for patients with non-Hodgkin lymphoma
  • Demonstrate greater confidence in their ability to
    • Personalize treatment for patients with non-Hodgkin lymphoma in an interprofessional team-based environment


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Christopher Flowers, MD, MS

    Chair and Professor
    Department of Lymphoma/Myeloma
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Disclosures

    Christopher Flowers, MD, MS, has the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie; Bayer; BeiGene; Celgene; Denovo; Epizyme; Janssen; Genentech; Genmab; Gilead; Karyopharm; Pharmacyclics; Roche; SeaGen, formerly Seattle Genetics, Inc.; Spectrum
    Received grants for clinical research from: 4D Pharma; AbbVie; Acerta; Adaptimmune; Allogene; Amgen; Bayer; Celgene; Cellectis; EMD Serono; Gilead; Genentech; Guardant; Iovance; Janssen; Kite; Morphosys; Nektar; Novartis; Pfizer; Pharmacyclics; Roche; Sanofi; Takeda; TG Therapeutics; Xencor; Ziopharm

  • Michael Buege, PharmD, BCOP

    Clinical Assistant Professor
    University of Illinois-Chicago College of Pharmacy
    Chicago, Illinois

    Disclosures

    Michael Buege, PharmD, BCOP, has no relevant financial relationships.

  • Amy Goodrich, RN, MSN, CRNP-AC

    Research Associate
    The Johns Hopkins School of Medicine
    Nurse Practitioner
    The Sidney Kimmel Cancer Center at Johns Hopkins
    Baltimore, Maryland

    Disclosures

    Participation by Dr Goodrich does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System.

    Amy Goodrich, RN, MSN, CRNP-AC, has no relevant financial relationships.

  • Kami Maddocks, MD

    Professor of Clinical Internal Medicine
    Division of Hematology
    The Ohio State University
    Columbus, Ohio

    Disclosures

    Kami Maddocks, MD, has the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie; ADC Therapeutics; Acerta; AstraZeneca; BeiGene; Bristol Myers Squibb Company; Genentech; Genmab; Gilead; Incyte; Janssen; Kite; Morphosys; Pharmacyclics
    Received grants for clinical research from: Bristol Myers Squibb Company; Pfizer; Pharmacyclics

  • Loretta Nastoupil, MD

    Deputy Chair
    Section Chief, Indolent Lymphoma and New Drug Development
    Director, Lymphoma Outcomes Database
    University of Texas
    MD Anderson Cancer Center
    Houston, Texas

    Disclosures

    Loretta Nastoupil, MD, has the following relevant financial relationships:
    Served as an advisor or consultant for: ADC Therapeutics; Bristol Myers Squibb Company; Genentech; Genmab; Gilead; Kite; Janssen; Morphosys; Novartis; Takeda
    Received grants for clinical research from: Bristol Myers Squibb Company; Caribou; Epizyme; Genentech; Gilead; IGM Biosciences; Janssen; Kite; Novartis; Takeda
    Contracted researcher for: ADC Therapeutics; Genmab

  • Gilles Salles, MD, PhD

    Professor of Medicine
    Chief of the Lymphoma Service
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Disclosures

    Gilles Salles, MD, PhD, has the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie; BeiGene; Bristol Myers Squibb Company; Celgene; Debiopharm; Epizyme; Genentech; Genmab; Gilead; Incyte; Ipsen; Janssen; Kite; Loxo; Miltenyi Biotec; Molecular Partners; Nordic Nanovector; Novartis; Rapt; Roche; Takeda; VelosBio
    Owns stock, stock options, or bonds from: Owkin

Editor

  • Sanneke Koekkoek

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Sanneke Koekkoek, has no relevant financial relationships.

Compliance Reviewer

  • Yaisanet Oyola, MD

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Yaisanet Oyola, MD, has no relevant financial relationships.

Nurse Planner

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 1.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.0 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs) (Universal Activity Number: JA0007105-0000-22-353-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Non-Hodgkin Lymphomas

Authors: Christopher Flowers, MD, MS; Michael Buege, PharmD, BCOP; Amy Goodrich, RN, MSN, CRNP-AC; Kami Maddocks, MD; Loretta Nastoupil, MD; Gilles Salles, MD, PhDFaculty and Disclosures

CME / ABIM MOC / CE Released: 10/13/2022

Valid for credit through: 10/13/2023

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Introduction Non-Hodgkin Lymphomas

Dr Flowers will let you know why you should join the sessions on non-Hodgkin lymphomas.
Christopher Flowers, MD, MS

Evolving Treatment Landscape in Diffuse Large B-Cell Lymphoma

Do you know there is a new treatment for patients with newly diagnosed diffuse large B-cell lymphoma?
Gilles Salles, MD, PhD

A Comprehensive Update on Mantle Cell Lymphoma

Are there new treatment approaches for patients with mantle cell lymphoma?
Kami Maddocks, MD

The Latest Updates in Follicular Lymphoma

Do we already know what the optimal sequencing of therapy is for patients with follicular lymphoma?
Loretta Nastoupil, MD

Panel: Case Discussions

Meet Tom, Sarah, and Rita who are diagnosed with non-Hodgkin lymphoma. How would you treat?
Christopher Flowers, MD, MS; Michael Buege, PharmD, BCOP; Amy Goodrich, RN, MSN, CRNP-AC

Panel Discussion

Watch experts across the professions discuss the team approach to caring for patients with non-Hodgkin lymphoma.
Christopher Flowers, MD, MS; Michael Buege, PharmD, BCOP; Amy Goodrich, RN, MSN, CRNP-AC; Kami Maddocks, MD; Loretta Nastoupil, MD; Gilles Salles, MD, PhD